Renier J Brentjens

Renier J Brentjens

UNVERIFIED PROFILE

Are you Renier J Brentjens?   Register this Author

Register author
Renier J Brentjens

Renier J Brentjens

Publications by authors named "Renier J Brentjens"

Are you Renier J Brentjens?   Register this Author

78Publications

2296Reads

42Profile Views

Application of CAR T cells for the treatment of solid tumors.

Prog Mol Biol Transl Sci 2019 23;164:293-327. Epub 2019 Jul 23.

Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, United States; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18771173193011
Publisher Site
http://dx.doi.org/10.1016/bs.pmbts.2019.07.004DOI Listing
July 2019

CARs of the future.

Am J Hematol 2019 May 25;94(S1):S55-S58. Epub 2019 Feb 25.

Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25416
Publisher Site
http://dx.doi.org/10.1002/ajh.25416DOI Listing
May 2019

Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.

EBioMedicine 2019 Jan 20;39:173-181. Epub 2018 Dec 20.

Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, China; International Center of Future Science, Jilin University, Changchun, China; Columbia Center for Translational Immunology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523964183058
Publisher Site
http://dx.doi.org/10.1016/j.ebiom.2018.12.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354733PMC
January 2019

Tumors evading CARs-the chase is on.

Nat Med 2018 10;24(10):1492-1493

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41591-018-0212-6
Publisher Site
http://dx.doi.org/10.1038/s41591-018-0212-6DOI Listing
October 2018

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Leuk Lymphoma 2018 09 6;59(9):2056-2067. Epub 2017 Nov 6.

d Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1393668DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936668PMC
September 2018

Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.

Mol Ther 2018 08 15;26(8):1896-1905. Epub 2018 Jun 15.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2018.05.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094824PMC
August 2018

Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.

Biol Blood Marrow Transplant 2018 06 1;24(6):1135-1141. Epub 2018 Mar 1.

Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.02.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625528PMC
June 2018

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.

Mol Ther 2018 06 28;26(6):1447-1456. Epub 2018 Mar 28.

Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2018.03.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986730PMC
June 2018

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.

N Engl J Med 2018 02;378(5):449-459

From the Leukemia Service, Department of Medicine (J.H.P., C.S., P.M., R.J.B.), the Michael G. Harris Cell Therapy and Cell Engineering Facility (I.R., X.W., B. Sénéchal, Y.W.), the Center for Cell Engineering (J.H.P., I.R., X.W., R.J.B., M.S.), and the Departments of Epidemiology and Biostatistics (M.G.), Pediatrics (K.J.C.), Neurology (B. Santomasso), Anesthesiology and Critical Care Medicine (E.M.), and Pathology (M.R.), Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Joan and Sanford Weill Medical College of Cornell University (J.H.P., C.S., R.J.B.) - all in New York; and the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL (M.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709919DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637939PMC
February 2018

Adoptive T-Cell Therapy for Solid Tumors.

Am Soc Clin Oncol Educ Book 2017 ;37:193-204

From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medicine, New York, NY; Center for Cell Engineering, and Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_180328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549627PMC
December 2017

Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.

J Natl Compr Canc Netw 2017 11;15(11):1429-1437

From Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medicine, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2017.7045DOI Listing
November 2017

Development of CAR T cells designed to improve antitumor efficacy and safety.

Pharmacol Ther 2017 Oct 22;178:83-91. Epub 2017 Mar 22.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology & Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2017.03.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601024PMC
October 2017

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.

Sci Rep 2017 09 5;7(1):10541. Epub 2017 Sep 5.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-10940-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585170PMC
September 2017

Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies.

Nat Rev Clin Oncol 2017 06 11;14(6):333-334. Epub 2017 Apr 11.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.49DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536112PMC
June 2017

At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.

J Leukoc Biol 2016 12 27;100(6):1255-1264. Epub 2016 Oct 27.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1189/jlb.5BT1215-556RRDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608016PMC
December 2016

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.

Cytotherapy 2016 11 31;18(11):1393-1409. Epub 2016 Aug 31.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067198PMC
http://dx.doi.org/10.1016/j.jcyt.2016.07.003DOI Listing
November 2016

CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.

Clin Adv Hematol Oncol 2016 Oct;14(10):802-808

Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536094PMC
October 2016

Toxicity and management in CAR T-cell therapy.

Mol Ther Oncolytics 2016 20;3:16011. Epub 2016 Apr 20.

Department of Pediatrics, Memorial Sloan Kettering Cancer Center , New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/mto.2016.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008265PMC
September 2016

Driving CAR T-cells forward.

Nat Rev Clin Oncol 2016 06 22;13(6):370-83. Epub 2016 Mar 22.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.36DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529102PMC
June 2016

Medical management of side effects related to CAR T cell therapy in hematologic malignancies.

Expert Rev Hematol 2016 06 19;9(6):511-3. Epub 2016 May 19.

b Department of Medicine , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2016.1183479DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539903PMC
June 2016

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Blood 2016 06 20;127(26):3312-20. Epub 2016 May 20.

Department of Medicine, Center for Cell Engineering, and Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-02-629063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929923PMC
June 2016

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Nat Rev Clin Oncol 2016 May 15;13(5):273-90. Epub 2016 Mar 15.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551685PMC
May 2016

Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.

Biochem Soc Trans 2016 Apr;44(2):412-8

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, U.S.A. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, U.S.A. Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BST20150291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529098PMC
April 2016

Novel immunotherapies in lymphoid malignancies.

Nat Rev Clin Oncol 2016 Jan 3;13(1):25-40. Epub 2015 Nov 3.

Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916838PMC
January 2016

Are chimeric antigen receptor T cells ready for prime time?

Clin Adv Hematol Oncol 2016 Jan;14(1):17-9

Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238717PMC
January 2016

Overcoming Antigen Escape with CAR T-cell Therapy.

Cancer Discov 2015 Dec;5(12):1238-40

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York. Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-1275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536095PMC
December 2015

Chimeric antigen receptor T cells for cancer immunotherapy.

J Clin Oncol 2015 May 20;33(15):1703-6. Epub 2015 Apr 20.

Memorial Sloan Kettering Cancer Center, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.3449DOI Listing
May 2015

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.

J Transl Med 2015 Mar 28;13:102. Epub 2015 Mar 28.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-015-0460-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438636PMC
March 2015

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors .

Oncoimmunology 2015 Mar 23;4(3):e994446. Epub 2015 Jan 23.

Department of Medicine; Memorial Sloan-Kettering Cancer Center ; New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/2162402X.2014.994446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404840PMC
March 2015

Are all chimeric antigen receptors created equal?

J Clin Oncol 2015 Feb 20;33(6):651-3. Epub 2015 Jan 20.

Memorial Sloan Kettering Cancer Center, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.5472DOI Listing
February 2015

CD28z CARs and armored CARs.

Cancer J 2014 Mar-Apr;20(2):127-33

From the *Department of Medicine, †Center for Cell Engineering, and ‡Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Centre, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687893PMC
November 2014

Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells.

Leuk Res Rep 2014 20;3(2):38-41. Epub 2014 May 20.

Departments of Medicine (M.A.D., E.B.P., S.C.J., R.J.B.) and Pathology (S.C.J., C.V.H.), Memorial Sloan-Kettering Cancer Center, New York, N.Y. 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lrr.2014.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050285PMC
June 2014

Immunotherapies in CLL.

Adv Exp Med Biol 2013 ;792:241-57

Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4614-8051-8_11DOI Listing
February 2014

Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy.

Stem Cells Dev 2013 Jul 28;22(13):1861-9. Epub 2013 Mar 28.

Department of Medicine (Hematology, Oncology, and Transplant), University of Minnesota, Minneapolis, Minnesota 55455, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/scd.2012.0608DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685314PMC
July 2013

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

Hematology Am Soc Hematol Educ Program 2012 ;2012:143-51

Memorial Sloan-Kettering Cancer Center, New York, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2012.1.143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536093PMC
June 2013

Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.

J Gene Med 2012 Jun;14(6):405-15

Memorial Sloan-Kettering Cancer Center - Bone Marrow Transplant Service, Department of Pediatrics, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jgm.2604DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697438PMC
June 2012

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Blood 2012 May 21;119(18):4133-41. Epub 2012 Feb 21.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-12-400044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359735PMC
May 2012

CARs and cancers: questions and answers.

Blood 2012 Apr;119(17):3872-3

Memorial Sloan-Kettering Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-02-410373DOI Listing
April 2012

Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.

Discov Med 2010 Apr;9(47):277-88

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697441PMC
April 2010

Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer.

Discov Med 2010 Jan;9(44):62-70

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
January 2010

Cellular therapies in acute lymphoblastic leukemia.

Curr Opin Mol Ther 2009 Aug;11(4):375-82

Memorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694559PMC
August 2009

Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase.

Nat Med 2009 Mar 15;15(3):338-44. Epub 2009 Feb 15.

Department of Radiology, Memorial Sloan Kettering Cancer Center (MSKCC), 1275 York Avenue, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.1930DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837150PMC
March 2009

T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.

Nat Med 2007 Dec 18;13(12):1440-9. Epub 2007 Nov 18.

Center for Cell Engineering, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm1676DOI Listing
December 2007

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

Clin Cancer Res 2007 Sep 12;13(18 Pt 1):5426-35. Epub 2007 Sep 12.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0674DOI Listing
September 2007

Novel approaches to the immunotherapy of B-cell malignancies: An update.

Curr Hematol Malig Rep 2006 Dec;1(4):258-63

Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-006-0007-6DOI Listing
December 2006

Novel approaches to immunotherapy for B-cell malignancies.

Curr Hematol Rep 2005 Jan;4(1):64-72

Hematology/Oncology Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
January 2005

Somatic cell engineering and the immunotherapy of leukemias and lymphomas.

Adv Pharmacol 2004 ;51:347-70

Department of Medicine and Clinical Laboratories, Leukemia Service Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1054-3589(04)51015-3DOI Listing
December 2004

Novel approaches to immunotherapy for B-cell malignancies.

Curr Oncol Rep 2004 Sep;6(5):339-47

Hematology/Oncology Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
September 2004

Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes.

Curr Hematol Rep 2004 Jul;3(4):290-7

Department of Medicine, Gene Transfer and Somatic Cell Engineering Laboratory, Immunology Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
July 2004

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Nat Biotechnol 2002 Jan;20(1):70-5

Department of Human Genetics/Medicine, Gene Transfer and Somatic Cell Engineering Laboratory, and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nbt0102-70
Publisher Site
http://dx.doi.org/10.1038/nbt0102-70DOI Listing
January 2002